LONDON: The owner of the Indian Serum Institute, Family of Poonawalla, has announced a donation of £ 50 million (RS 500 Crore) to Oxford University to build a new research center that focuses on vaccinology.
Donations from serum life science, fully owned by the Poonawalla family, is the largest gift of Oxford University for vaccine research.
This will be used to make new facilities to accommodate more than 300 research scientists on the old road campus.
Named after the research of the Poonawalla vaccine, it will accommodate the head office and the main laboratory space of Jenner Institute where the University of Oxford / Astrazeneca Covid-19 vaccines are developed, as well as other leading Oxford teams such as those who develop malaria vaccines.
It will be built on the same site as the University of Pandemi Pandemi Science Center which was recently announced and two buildings will share infrastructure and supporting facilities for scientific research and academic teaching and together will form a unique hub that will contribute to the readiness of global pandemics .
Professor Louise Richardson, Chancellor of the University of Oxford, said: “The university has a long relationship with the Poonawalla family and we are happy to provide an honorary title about Cyrus Poonawalla in the summer of 2019 in recognition of its extraordinary expensive vaccine.
The world that develops.
I am happy That through this generous gift, we will be able to advance our work on vaccines that have been proven to be very important for global health.
“Collaborative Institute of Serum Institute of Serum-Jenner includes an agreement for the Serum Institute to produce and develop, with large-scale supplies, vaccines Malaria Jenner Institute promises, currently in phase III trials, prioritize countries with high malaria burdens.
Prof.
Adrian Hill, Director of Jenner Institute, said the success of collaboration between the University and Serum Institute of Malaria Vaccine and Covid-19 highlighted the potential of partnerships between universities and producers to develop and supply vaccines effectively on a scale.